Announced details
Royalties equivalent to 8–16% of F351's annual sales revenue. The number of F351 patients in China alone is estimated to reach several million at peak.
Ayumi Pharmaceutical recorded sales revenue of ¥10.8 billion and operating profit of ¥1.8 billion from July to September 2026. Gyre Pharmaceuticals covers thousands of hospitals.
Gyre Therapeutics and Gyre Pharmaceuticals are affiliated companies of the group. 上海ジェノミックス is a wholly owned subsidiary of the company. The group has an intercompany licensing agreement for F351. Ayumi Pharmaceutical became a group company after being made a subsidiary.
NMPA is China's drug regulatory authority. Gyre Therapeutics is listed on the Nasdaq Stock Market in the United States. 上海ジェノミックス is a wholly owned subsidiary of the company. Gyre Pharmaceuticals has a sales and marketing organization of approximately 400 people in China, covering thousands of hospitals. Ayumi Pharmaceutical has a domestic sales network and production capabilities in the pain and rheumatology fields.
London, UK (conference venue)
F351 is an important drug candidate expected to drive medium- to long-term growth and contribute to sales and profit growth upon launch. The group aims to grow to several times its current group sales revenue of approximately ¥47 billion.
The company does not address Contract Value / Offering price.
The disclosure contains wording suggesting information published by the World Health Organization and other organizations, but does not identify the specific organizations in the main text. It states that market data and other information were cited from publicly available sources deemed reliable.
| Item | Details |
|---|---|
| Names of Products / Services Covered | F351, Aisurui, Targeted protein degraders, TRK protein degrader, GSPT1 protein degrader, CDK2 protein degrader, TYK2 protein degrader, Aesthetic medical products |
| Counterparty | China's National Medical Products Administration (NMPA), Gyre Therapeutics(NASDAQ: GYRE), Gyre Pharmaceuticals, あゆみ製薬, 上海ジェノミックス, Jefferies |
| Counterparty overview | NMPA is China's drug regulatory authority. Gyre Therapeutics is listed on the Nasdaq Stock Market in the United States. 上海ジェノミックス is a wholly owned subsidiary of the company. Gyre Pharmaceuticals has a sales and marketing organization of approximately 400 people in China, covering thousands of hospitals. Ayumi Pharmaceutical has a domestic sales network and production capabilities in the pain and rheumatology fields. |
| Relationship with the Company | Gyre Therapeutics and Gyre Pharmaceuticals are affiliated companies of the group. 上海ジェノミックス is a wholly owned subsidiary of the company. The group has an intercompany licensing agreement for F351. Ayumi Pharmaceutical became a group company after being made a subsidiary. |
| Launch date | F351 is expected to launch in the first half of 2027, subject to regulatory approval. |
| Applicable area | Liver fibrosis associated with hepatitis B, Cancer, Immune and inflammatory diseases, including rheumatic diseases, Aesthetic Medicine |
| Location | London, UK (conference venue) |
| Location scale | Gyre Pharmaceuticals has a sales and marketing organization of approximately 400 people, covering thousands of hospitals |
| Quantitative Effects | Royalties equivalent to 8–16% of F351's annual sales revenue. The number of F351 patients in China alone is estimated to reach several million at peak. |
| Usage history | Ayumi Pharmaceutical recorded sales revenue of ¥10.8 billion and operating profit of ¥1.8 billion from July to September 2026. Gyre Pharmaceuticals covers thousands of hospitals. |
| Impact on Business Performance | F351 is an important drug candidate expected to drive medium- to long-term growth and contribute to sales and profit growth upon launch. The group aims to grow to several times its current group sales revenue of approximately ¥47 billion. |
| Source | The disclosure contains wording suggesting information published by the World Health Organization and other organizations, but does not identify the specific organizations in the main text. It states that market data and other information were cited from publicly available sources deemed reliable. |
Items this document does not state (6)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To enhance information dissemination and ensure fair disclosure.